RxDoctor Payments Data

Sameer Jamal, MD

Clinical Cardiac Electrophysiology · Hackensack, NJNPI 1245455799

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $33,550 of the $44,008 with a category attached, or 76.2%. 24 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 57.6% of the total. Reporting peaked in 2019 at $10,778 and has fallen 88.8% since, to $1,207 in 2025.

$44,008in general payments, 2019–2025

Across 257 payments — averaging $171.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$25K
  • Impulse Dynamics (USA) Inc.$9K
  • Medtronic$3K
  • Boston Scientific$2K
  • Biotronik Inc.$1K
  • Altathera Pharmaceuticals LLC$1K
  • plus $2K from 18 others
$64,596in research payments, 2019–2025

Across 2 payments — averaging $32,298 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Impulse Dynamics (USA) Inc.$65K

What the payments were for

  • Consulting fees$1750%
  • Speaking & faculty fees$33,55076%
  • Travel & lodging$2,5456%
  • Food & beverage$7,73818%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,008 in reported general payments places this provider in the 80th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$159,542
Medicare patients
889
Services billed
2,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$88,813
MultaqDronedarone Hcl16$23,858
XareltoRivaroxaban14$21,159
Flecainide Acetate31$1,267
Amiodarone Hcl62$1,115
Metoprolol Succinate40$498
Verapamil ErVerapamil Hcl12$355
Carvedilol17$304
Metoprolol Tartrate25$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$88,81377 claims
Sanofi-aventis U.S. LLCMultaq$80$23,85816 claims
Johnson & JohnsonXarelto$139$21,15914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →